The price and medical insurance coverage of elalastran in 2025

Elacestrant is indicated primarily for the treatment of metastatic or locally advanced estrogen receptor-positive (ER+) breast cancer, particularly in patients who have developed endocrine resistance. Breast cancer is one of the most common female malignant tumors, and about 70% to 80% of breast cancer patients are estrogen receptor-positive. Treatment of estrogen receptor-positive breast cancer usually relies on endocrine therapy, but over time, some patients will develop resistance to traditional endocrine therapy, and elastran is a therapy designed for such patients. By binding to estrogen receptors, elastran effectively inhibits the biological activity of estrogen, reduces the proliferation of cancer cells, and prolongs the progression-free survival (PFS) of patients.

Elastran is used clinically to replace or supplement other endocrine therapy regimens, especially in patients with breast cancer that have developed drug resistance. By selectively modulating the activity of estrogen receptors, elastran has a unique mechanism of action and has certain advantages compared with other endocrine therapy drugs, especially in cases of drug resistance or relapse.

At present, elastran has not yet been launched in China, so the price in the domestic market has not yet been determined. According to the situation in overseas markets, the price of the original drug of elastran in Europe and other regions is approximately more than 30,000 yuan per box. The relatively cheaper version is a generic drug from Laos. The price is about more than 2,000 yuan per box, and the ingredients of the drug are basically the same as the original drug, so it has a good price/performance ratio. However, because elastran has not yet entered the Chinese market, patients are currently unable to purchase the drug domestically through formal channels.

In terms of medical insurance coverage, elastran is not included in the scope of medical insurance reimbursement in China. Because this drug is still an imported drug and has been on the market for a short time, it is temporarily unable to enjoy the medical insurance reimbursement policy. For patients, they may need to purchase this drug through international drug purchasing or other overseas channels, and decide whether to choose this treatment option based on their personal financial situation.

Reference materials：https://www.drugs.com/mtm/elacestrant.html